| Name | Title | Contact Details |
|---|
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.
We are dedicated to quality service for the medically fragile child. We service our patients based on each child's specific needs to develop their potential through clinical education and technical support. We believe it takes more than health care to
The Mental Health Association of South Central Kansas (MHASCK) has been serving the Sedgwick County Community since 1957. We are a 501(c)3 non-profit organization, a United Way agency and an affiliate of Sedgwick County COMCARE. We believe these
Birmingham Gastroenterology Associates is a medical practice that specializes in the treatment of diseases and disorders of the digestive tract, including the esophagus, stomach, intestines, liver and pancreas.
Regulatory Presentation Management is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.